#USA #Boston #Huntington's Disease #Skyhawk Therapeutics #SKY-0515

Skyhawk Therapeutics Reports Promising Phase 1/2 Results

Skyhawk Therapeutics, a clinical-stage biotechnology company renowned for its innovative RNA-targeted therapies, has recently disclosed the final fifteen-month findings from its Phase 1/2 clinical trial focusing on SKY-0515. This investigational oral treatment aims to combat Huntington's disease (HD), a rare and severe neurodegenerative condition affecting thousands globally.

Overview of the Study

The trial was structured as a randomized, double-blind, placebo-controlled study to evaluate two dosage levels of SKY-0515 administered to patients over 12 weeks, followed by an additional 12-month extension period where all participants received either a low (4 mg) or high (9 mg) dose. A substantial number of participants were treated with the higher dose.

At the primary Month 15 analysis, those who received SKY-0515 showcased an average improvement of 0.94 points on the Composite Unified Huntington's Disease Rating Scale (cUHDRS), in stark contrast to a decline of 0.65 points noted in the untreated control group from the Enroll-HD database. This marked a significant treatment difference of 1.59 points, reaching statistical significance (p<0.001).

Key Findings of the Trial

Patients receiving SKY-0515 not only improved overall in the cUHDRS measures but excelled in each of the four key areas: Total Functional Capacity (TFC), Total Motor Score (TMS), as well as cognitive tasks such as the Symbol Digit Modalities Test (SDMT) and the Stroop Word Reading Test (SWRT). Each of these assessments produced statistically significant benefits, suggesting that SKY-0515 effectively enhances functional abilities and cognitive performance in HD patients.

The study also indicated that SKY-0515 consistently reduced levels of mutant huntingtin protein (mHTT)—the key protein implicated in the pathology of Huntington's disease—by over 60%, along with a reduction in PMS1 mRNA of more than 25%. These findings reinforce the drug's dual-action approach against two major pathogenic mechanisms of the disease.

Broader Implications

Skyhawk is optimistic about the broad implications this research has for advancing the treatment of Huntington's disease. There are currently no approved therapies that can slow or stop the progression of this devastating condition, which impacts more than 40,000 individuals in the United States alone. As Dr. Samuel Frank, Director of the Huntington's Disease Society of America Center of Excellence put it, “The consistent effects on function, motor and cognitive measures need to be further studied in ongoing placebo-controlled studies, but it is an exciting step forward for HD and the program.”

Moreover, this research holds particular promise due to the ease of administration; SKY-0515 is designed to be taken orally once a day, allowing greater accessibility to patients who may struggle to obtain specialized care. This aspect particularly resonates with advocates like Katie Jackson, CEO of Help 4 HD International, who emphasized that this treatment could significantly reach underserved patients worldwide.

Conclusion

The findings from SKY-0515’s Phase 1/2 trial position Skyhawk Therapeutics at the forefront of innovative solutions for Huntington's disease. Their commitment to advancing therapies targeting neurological disorders through their proprietary SKYSTAR platform is noteworthy, with hopes of launching more novel treatments by the conclusion of 2027. With the Phase 2/3 FALCON-HD pivotal study now active across ten countries, this could represent a significant breakthrough in the management and treatment options available for individuals affected by Huntington's disease. As the clinical landscape evolves, the results from this trial may very well be a turning point for the estimated hundreds of thousands of families dealing with this relentless condition.